Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Shares OutstandingShares Outstanding (Weighted Average)
Others
Receivables - OtherReceivables RefundsShares OutstandingShares Outstanding
Ratios

Telix Pharmaceuticals (TLX) Shares Outstanding (2024 - 2025)

Telix Pharmaceuticals has reported Shares Outstanding over the past 2 years, most recently at $338.8 million for Q4 2025.

  • Quarterly Shares Outstanding rose 54.77% to $338.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $338.8 million through Dec 2025, up 54.77% year-over-year, with the annual reading at $338.8 million for FY2025, 54.77% up from the prior year.
  • Shares Outstanding was $338.8 million for Q4 2025 at Telix Pharmaceuticals, up from $218.9 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $338.8 million in Q4 2025 and troughed at $218.9 million in Q4 2024.